Document is current
Any future updates will be listed below
-
Authors
Liu, Wei https://orcid.org/0000-0001-6435-6696
Cao, Hongchao
Wang, Jing
Elmusrati, Areeg
Han, Bing
Chen, Wei
Zhou, Ping
Li, Xiyao
Keysar, Stephen
Jimeno, Antonio
Wang, Cun-Yu https://orcid.org/0000-0002-3885-5149
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE030445, R01DE029173)
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA236878)
- License Information
-
More Information
Article History
Received: 6 December 2023
Accepted: 24 July 2024
First Online: 8 August 2024
Competing interests
: W.L., H.C., and C.Y.W. are listed as inventors on intellectual property owned by UCLA related to targeting KMT2D-mutant tumors. CYW received research funding unrelated to this project from RNAimmune Inc, is a co-founder and equity holder in WZJ Therapeutics and has served as a compensated consultant for Curigin Inc and Acroimmune Inc, all unrelated to the current work. AJ has stock/options ownership in Suvica and Champions Oncology; AJ institution has contracts with Cantargia, DebioPharm, Genentech, Iovance, Khar Biopharma, Merck, Moderna, Pfizer, Sanofi, and SQZ for clinical trials where AJ is the local PI. C.Y.W., W.L., and H.C. have filed a patent application for the findings reported in the manuscript. The remaining authors declare no competing interests.
